CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...

For EYLEA HD, label expansions and a prefilled syringe are expected to drive uptake. Libtayo is targeting new approvals in skin and lung cancers. Dupixent is expanding into COPD, chronic urticaria ...

For one, the prefilled syringe, which we know physicians have a strong preference for it is expected to launch by midyear. The RVO indication which is nearly 20% of EYLEA business is for the RVO ...